StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals Total Accounts Receivable, Net by Quarter

Total Accounts Receivable, Net ($M) ($M)

Regeneron Pharmaceuticals Total Accounts Receivable, Net: $7,579M in Q3 2026, up 33.3% from a year earlier. That is the highest of the 67 quarters on record here.

Latest, Q3 2026
7,579
Period ended Sep 30, 2026
Change on a year earlier
+33.3%
5,687 in Q3 2025
History
67 quarters
Since Q4 2009
Sources
58
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K Consolidated Balance Sheets & Concentration Note.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Accounts Receivable, Net ($M) ($M)Year on yearSource
Q3 2026Sep 30, 20267,579+33.3%Form 10-Q (filed 2026-10-30) ↗
Q2 2026Jun 30, 20266,565+17.0%Form 10-Q (filed 2026-07-30) ↗
Q1 2026Mar 31, 20265,731+3.1%Form 10-Q (filed 2026-04-29) ↗
Q4 2025Dec 31, 20255,741-7.6%Form 10-Q (filed 2026-10-30) ↗
Q3 2025Sep 30, 20255,687-6.9%Form 10-Q (filed 2025-10-28) ↗
Q2 2025Jun 30, 20255,610-1.9%Form 10-Q (filed 2025-08-01) ↗
Q1 2025Mar 31, 20255,561+6.5%Form 10-Q (filed 2025-04-29) ↗
Q4 2024Dec 31, 20246,212+9.6%Form 10-K (filed 2026-02-04) ↗
Q3 2024Sep 30, 20246,107+9.4%Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 20245,717+11.6%Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 20245,222+2.0%Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 20235,667+6.4%Form 10-K (filed 2025-02-05) ↗
Q3 2023Sep 30, 20235,585+0.7%Form 10-Q (filed 2023-11-02) ↗
Q2 2023Jun 30, 20235,121-0.8%Form 10-Q (filed 2023-08-03) ↗
Q1 2023Mar 31, 20235,119+5.8%Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 20225,329-11.7%Form 10-K (filed 2024-02-05) ↗

Breakdown

What makes up total Accounts Receivable, Net

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Total Accounts Receivable, Net ($M), quarterly Q4 2009–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/ar-total

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?